512-64-1
中文名称
醌霉素A
英文名称
QUINOMYCIN A
CAS
512-64-1
分子式
C51H64N12O12S2
分子量
1101.26
MOL 文件
512-64-1.mol
更新日期
2024/05/27 15:00:43
512-64-1 结构式
基本信息
中文别名
棘霉素醌霉素A
英文别名
SK-302Bnsc526417
NSC 13502
ECHINOMYCIN
QUINOMYCIN A
echinomycina
Echinomycin >97%
Antibiotic A 654I
Echinomycin (NSC-13502)
EchinoMycin, Actinoleukin, 1491, 59266, X 948, X 53III
物理化学性质
熔点217-218℃
比旋光度D20 -310° (c = 0.86 in chloroform)
密度1.0964 (rough estimate)
折射率1.6700 (estimate)
储存条件-20°C
储存条件2-8°C
溶解度溶于DMSO（高达5mg/ml）
形态白色固体
颜色白色至米色
Merck13,3531
稳定性可在-20°C下DMSO溶液中保存长达3个月
安全数据
警示词危险
危险性描述H301+H311+H331-H361
危险品标志T
危险类别码46-23/24/25
安全说明53-36/37/39-45
危险品运输编号UN 3462 6.1/PG 2
危险品运输编号UN 3462 6.1/PG 2
WGK Germany3
WGK Germany3
RTECS号JW5250000
F10
危险等级6.1(b)
包装类别III
海关编码2941900000
常见问题列表
生物活性
Echinomycin (Quinomycin A) 是一种有效的,细胞渗透性的低氧诱导因子-1 (HIF-1) DNA 结合活性的小分子抑制剂。Echinomycin 选择性抑制癌症干细胞，其 IC50 值为 29.4 pM。体外研究
Echinomycin (0-10 nM; 16 hours; U251 cells) treatment significantly inhibits hypoxia-induced VEGF mRNA expression in a dose-dependent fashion. Echinomycin very potently inhibits hypoxic induction of luciferase expression in U251-HRE in a dose-dependent fashion with an EC 50 of 1.2 nM.
RT-PCR
| Cell Line: | U251 cells |
| Concentration: | 0 nM, 0.625 nM, 1.25 nM, 5 nM, 10 nM |
| Incubation Time: | 16 hours |
| Result: | Significantly inhibited VEGF mRNA expression induced by hypoxia in a dose-dependent fashion. |
体内研究
Echinomycin (10 μg/kg; intravenous injection; for 40 days; NOD-SCID mice) treatment efficiently eradicates mouse lymphoma and serially transplantable human acute myeloid leukemia (AML) in xenogeneic model by preferential elimination of cancer stem cells (CSCs). HIF1α maintains mouse lymphoma CSCs by repressing a negative feedback loop in the Notch pathway.
| Animal Model: | NOD-SCID mice received 1.8Gy of irradiation and i.v. injection with peripheral blood cells from patients AML-71 and AML-150 |
| Dosage: | 10 μg/kg |
| Administration: | Intravenous injection; for 40 days |
| Result: | Efficiently eradicated mouse lymphoma and serially transplantable human AML in xenogeneic model by preferential elimination of CSCs. |